PT-141 (Bremelanotide): What the Research Says About Sexual Health

Sexual health is a core dimension of overall wellbeing, and for many people, reduced sexual desire creates real distress. Yet for much of modern medicine's history, pharmacological options for this concern, particularly for women, were limited. PT-141 bremelanotide (the compound that became the FDA-approved drug Vyleesi) emerged from a different approach: rather than targeting blood flow, it acts on the brain itself.

This article explores what the published research says about PT-141 (bremelanotide), how it works mechanistically, and what clinical trials have found. This is an educational overview. It is not medical advice, and any decisions about treatment should involve a licensed healthcare provider.

*This article is for educational and research purposes only. PT-141 (bremelanotide) is FDA-approved as Vyleesi for HSDD in premenopausal women when administered as an injectable. Compounded versions of bremelanotide are not FDA-approved. Consult your healthcare provider before considering any treatment.*

---

What Is PT-141?

PT-141, also known as bremelanotide, is a synthetic peptide derived from a melanocyte-stimulating hormone (MSH) analog. It was originally investigated as a potential tanning agent, but researchers noticed an unexpected side effect in early studies: increased sexual arousal.

That discovery redirected its development entirely. After more than a decade of clinical trials, bremelanotide received FDA approval in June 2019 under the brand name Vyleesi, for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

PT-141 belongs to a class of compounds called melanocortin receptor agonists. Its mechanism of action sets it apart from every other approved treatment in the sexual health category.

---

How PT-141 Works: The Mechanism

Most medications for sexual dysfunction work peripherally, affecting blood vessels. PT-141 takes a fundamentally different approach: it acts centrally, engaging specific receptors in the brain.

PT-141 activates melanocortin receptors, particularly MC3R and MC4R, which are expressed in areas of the brain involved in sexual function and reward. Research suggests these receptors play a role in modulating sexual motivation and arousal pathways in the central nervous system.

This central mechanism explains why PT-141 may help people for whom purely vascular approaches have been ineffective: desire is not simply a matter of blood flow. It is a complex neurological process involving motivation, reward signaling, and mood.

Studies in animal models established the neurological basis for this effect well before clinical trials began. Research published in peer-reviewed journals identified the role of melanocortin pathways in regulating sexual behavior across mammalian species, providing the mechanistic rationale for investigating PT-141 in humans.

---

What Hypoactive Sexual Desire Disorder Is

Hypoactive sexual desire disorder (HSDD) is the most common form of female sexual dysfunction. It is characterized by a persistent or recurrent absence of sexual fantasies and desire for sexual activity, which causes meaningful personal distress.

HSDD is not simply low libido as a passing phase. The diagnosis requires that the reduction in desire causes significant distress and cannot be fully explained by another medical condition, a relationship issue, or a medication side effect.

Estimates suggest HSDD affects somewhere between 8% and 15% of premenopausal women in the United States, though the figure is difficult to establish precisely given underreporting and varying diagnostic criteria.

---

What the Clinical Research Shows

The RECONNECT Trials

The most significant clinical evidence for bremelanotide comes from the RECONNECT trials, a pair of Phase 3 randomized, double-blind, placebo-controlled studies that together enrolled over 1,200 premenopausal women with HSDD.

Research published following these trials found that women using bremelanotide reported statistically significant improvements in sexual desire compared to placebo, as measured by validated instruments including the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). Women in the bremelanotide group also reported a greater reduction in distress related to their sexual function.

A study published in *Obstetrics and Gynecology* (Kingsberg et al., 2019, PMID: 31135728) reported that bremelanotide significantly increased the number of satisfying sexual events and reduced the distress associated with low sexual desire compared to placebo across both trials.

Earlier Dose-Finding Research

Phase 2 research established the dose-response relationship and safety profile that guided the larger trials. An earlier study published in *Psychopharmacology* (Clayton et al., 2016, PMID: 26563282) investigated bremelanotide in premenopausal women with female sexual dysfunction and found improvements in arousal, lubrication, and satisfaction scores. The research helped establish optimal dosing parameters for Phase 3 development.

Research on the Melanocortin Pathway

The mechanistic foundation of PT-141's effects rests on research into melanocortin receptors. A review published in *Current Topics in Medicinal Chemistry* (Shadiack et al., 2007, PMID: 17305569) summarized findings across studies examining melanocortins in the treatment of sexual dysfunction in both males and females, establishing the scientific basis for the central nervous system approach that distinguishes PT-141 from peripheral vasodilators.

---

*Research suggests sexual desire is regulated through complex neurological pathways involving melanocortin receptors in the brain, distinct from the vascular mechanisms targeted by most ED medications.*

---

How Bremelanotide Is Administered

In its FDA-approved form, bremelanotide (Vyleesi) is administered as a subcutaneous injection approximately 45 minutes before anticipated sexual activity. It is not taken daily. The recommended maximum is one dose per 24 hours and no more than one dose per week.

Compounded formulations may differ in delivery method or concentration. Compounded medications are not FDA-approved and should only be used under the supervision of a licensed healthcare provider who has evaluated your individual medical history.

---

Side Effects and Safety Considerations

The most common side effects reported in clinical trials include:

Nausea: The most frequently reported adverse event, occurring in approximately 40% of participants. Nausea typically begins within an hour of administration and resolves within a few hours. Pre-treating with an antiemetic before taking bremelanotide is an approach some providers consider.

Flushing: Warmth, redness, or tingling in the face, neck, or chest, reported in roughly 20% of participants.

Headache: Reported in a meaningful proportion of participants, usually mild to moderate in severity.

Blood pressure changes: Bremelanotide can cause a transient, usually short-lived increase in blood pressure followed by a decrease. For this reason, it is contraindicated in people with cardiovascular disease, uncontrolled hypertension, or known risk of cardiac events. Blood pressure typically returns to baseline within approximately 12 hours.

Hyperpigmentation: With repeated use, some people developed focal hyperpigmentation of the face, gums, or breasts. This was more common in people with darker skin tones. Discontinuing use typically halted progression.

People with cardiovascular disease should not use bremelanotide. Bremelanotide is not recommended during pregnancy. Always disclose your full medical history and current medications to your provider before any treatment.

---

Who the Research Suggests May Benefit

The clinical trials enrolled specifically premenopausal women with HSDD characterized by distress. Women who may find the research most relevant to discuss with a provider include those who:

• Experience significant personal distress related to low sexual desire
• Have not found improvement through lifestyle changes or relationship-focused approaches
• Do not have active cardiovascular disease or uncontrolled hypertension
• Are not pregnant or planning to become pregnant during treatment

Bremelanotide is not studied or indicated for postmenopausal women, men, or people whose low desire is primarily relationship-based rather than a physiological pattern.

---

PT-141 and Male Sexual Health

Early research investigated PT-141 in men with erectile dysfunction, including a study published in the *International Journal of Impotence Research* (Diamond et al., 2004, PMID: 15164094). While the research showed that the compound could produce effects in men, the clinical development pathway for males did not advance to FDA approval in the same manner it did for women. Research in this area continues.

---

Important Distinctions

Several distinctions are worth understanding when reviewing information about PT-141:

Bremelanotide vs. compounded PT-141: Vyleesi is the FDA-approved injectable form. Compounded versions of bremelanotide are not FDA-approved and may differ in formulation, concentration, or delivery method. Compounded medications should only be used under licensed provider supervision.

PT-141 vs. flibanserin (Addyi): Flibanserin (brand name Addyi) is the other FDA-approved treatment for HSDD. It is a daily oral medication with a different mechanism (affecting serotonin and dopamine pathways). It is not in the same drug class as bremelanotide and has its own distinct safety profile and interaction risks, including a serious alcohol interaction.

Sexual desire vs. arousal vs. performance: PT-141 research focuses on desire and, to a degree, arousal. It is not a medication designed to address physical performance in the same way that phosphodiesterase-5 inhibitors (sildenafil, tadalafil) address erectile function through vascular mechanisms.

---

What This Research Means for Clinical Practice

The approval of bremelanotide in 2019 marked a notable moment in sexual medicine: the second FDA-approved pharmacotherapy for women's sexual dysfunction and the first in its drug class.

Clinicians have varying approaches to prescribing it. Some find it most useful for women who have tried and not responded to flibanserin, or for whom daily medication is not preferred. Others find it useful as a first-line approach when the situational nature of sexual activity makes an on-demand treatment more practical.

Ongoing research continues to examine long-term safety, effects in different populations, and potential applications in male sexual health. The picture is still developing.

---

Frequently Asked Questions

Is PT-141 the same as Vyleesi? Bremelanotide is the active compound in both. Vyleesi is the FDA-approved branded injectable product. Compounded versions of bremelanotide exist but are not FDA-approved.

How quickly does it work? The FDA-approved form is designed for administration 45 minutes before anticipated sexual activity. The onset is not immediate.

Is this related to the tanning peptide Melanotan? PT-141 was derived from research into MSH analogs, the same family of compounds as Melanotan II. However, they are distinct compounds with different development histories and regulatory statuses. Melanotan II is not FDA-approved.

Does it work for everyone? No treatment works for everyone. In the RECONNECT trials, a meaningful proportion of women showed improvements over placebo, but not all participants responded. Individual responses vary significantly.

---

*This article is for educational and research purposes only. It does not constitute medical advice. Treatment decisions should always be made in partnership with a licensed healthcare provider who has reviewed your complete medical history.*

*Vyleesi (bremelanotide) is an FDA-approved treatment for HSDD in premenopausal women. Compounded bremelanotide is not FDA-approved and is not the same as, equivalent to, or interchangeable with Vyleesi. Do not self-administer any compound without consulting a licensed healthcare provider.*

*Vyleesi is a registered trademark of Palatin Technologies, Inc. Prescriva is not affiliated with, endorsed by, or sponsored by Palatin Technologies.*

---

Sources

1. Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. *Obstetrics and Gynecology.* 2019. [PMID: 31135728](https://pubmed.ncbi.nlm.nih.gov/31135728/)
2. Clayton AH, et al. Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. *Psychopharmacology.* 2016. [PMID: 26563282](https://pubmed.ncbi.nlm.nih.gov/26563282/)
3. Shadiack AM, et al. Melanocortins in the Treatment of Male and Female Sexual Dysfunction. *Current Topics in Medicinal Chemistry.* 2007. [PMID: 17305569](https://pubmed.ncbi.nlm.nih.gov/17305569/)

---

Talk to a Provider

Sexual health is part of whole-person health. If you are experiencing distress related to changes in sexual desire, speaking with a licensed healthcare provider is the most important first step. Prescriva connects you with providers who can evaluate your individual situation and discuss whether any treatment options are appropriate for you.

*Consult your healthcare provider. Results may vary. This is not medical advice.*

[Connect With a Provider](#)